Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 4/20 | 0.39 |
| ▸ | MC1R | Q01726 | 4/20 | 0.39 |
| ▸ | TSLP | Q969D9 | 2/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | CTSG | P08311 | 1/20 | 0.35 |
| ▸ | TACR2 | P21452 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20362936 | 0.96 | TSLP (0.39) | MC4RMC1RTSLPOPRM1OPRD1 | |
| SCHEMBL22606361 | 0.95 | MC4R (0.39) | MC4RMC1RTSLPOPRM1OPRD1 | |
| SCHEMBL20206173 | 0.95 | TSLP (0.39) | MC4RMC1RTSLPOPRM1OPRD1 | |
| SCHEMBL20362939 | 0.95 | TSLP (0.39) | MC4RMC1RTSLPOPRM1OPRD1 | |
| SCHEMBL22606167 | 0.92 | TSLP (0.39) | TSLPCTSGTACR2 | |
| SCHEMBL20363003 | 0.91 | MC4R (0.40) | MC4RMC1RTSLP | |
| SCHEMBL20206167 | 0.91 | FCGRT (0.39) | MC4RMC1RTSLP | |
| SCHEMBL20206196 | 0.90 | TUBB4A (0.38) | MC4RMC1RTSLPOPRM1OPRD1 | |
| SCHEMBL20362935 | 0.89 | TSLP (0.37) | MC1RTSLPOPRM1OPRD1OPRK1 | |
| SCHEMBL20206237 | 0.88 | TACR2 (0.42) | MC4RMC1RTSLPOPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11286280-B2 | Melanocortin-1 receptor-specific peptides for cytokine storm and inflammation therapy | PALATIN TECHNOLOGIES, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-20200339631-A1 | Melanocortin-1 Receptor-Specific Peptides for Cytokine Storm and Inflammation Therapy | PALATIN TECHNOLOGIES INC (US) | 2020-10-29 | — | — | US | disclosed |
| US-10711039-B2 | Melanocortin receptor-specific peptide with C-terminal naphthylalanine | PALATIN TECHNOLOGIES, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10017539-B2 | Melanocortin-1 receptor-specific cyclic hexapeptides | PALATIN TECHNOLOGIES, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20180148478-A1 | Melanocortin Receptor-Specific Peptide with C-Terminal Naphthylalanine | PALATIN TECHNOLOGIES INC (US) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10711039-B2 | Melanocortin receptor-specific peptide with C-terminal naphthylalanine | MC1R, MC3R, MC4R | MC4R 3/4885MC1R 1/4885TSLP 624/4885 |
| US-11286280-B2 | Melanocortin-1 receptor-specific peptides for cytokine storm and inflammation therapy | MC3R, MC1R, MC2R | MC4R 6/4885MC1R 2/4885TSLP 15/4885 |
| US-10017539-B2 | Melanocortin-1 receptor-specific cyclic hexapeptides | MC1R, MC3R, MC5R | MC4R 4/4885MC1R 1/4885TSLP 357/4885 |
| US-20200339631-A1 | Melanocortin-1 Receptor-Specific Peptides for Cytokine Storm and Inflammation Therapy | MC3R, MC1R, MC2R | MC4R 6/4885MC1R 2/4885TSLP 15/4885 |
| US-20180148478-A1 | Melanocortin Receptor-Specific Peptide with C-Terminal Naphthylalanine | MC1R, MC3R, MC4R | MC4R 3/4885MC1R 1/4885TSLP 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.